Mirvish S S, Huang Q, Williamson J, Chen S C, Gelboin H V
Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha 68198, USA.
Mutat Res. 1995 Sep;331(1):161-70. doi: 10.1016/0027-5107(95)00065-q.
The mutagenicity for Salmonella typhimurium TA 1535 of the carcinogen methyl-n-amylnitrosamine (MNAN) was examined in the presence of rat liver microsomes from uninduced and induced rats. The number of mutations followed the order phenobarbital- and Aroclor-induced > 3-methylcholanthrene- and isoniazid-induced > uninduced microsomes. The MNAN metabolite 4-hydroxy-MNAN was not mutagenic. Using each type of induced liver microsomes, we examined the effect on MNAN mutagenicity of four monoclonal antibodies (MAbs) that inhibit cytochrome P450s. The MAbs inhibited MNAN mutagenicity in seven MAb-microsome combinations by up to 49%. Taken together, these results indicated that CYP (P450) 2B1/2B2 was responsible for one half and CYP 2C11 for one quarter of MNAN mutagenicity with phenobarbital-induced microsomes, CYP 1A1/1A2 accounted for about 40% of the mutagenicity with 3-methylcholanthrene-induced microsomes, CYP 2B1/2B2 accounted for half and CYP 1A1/1A2 and 2C11 for smaller proportions of the mutagenicity with Aroclor-induced microsomes, and CYP 1A1/1A2 accounted for about 30% of the mutagenicity with isoniazid-induced microsomes. With isoniazid-induced microsomes, MAb 2-66-3 to CYP 2B1/2B1 caused an unexpected 219% increase and MAb 1-68-11 caused a moderate increase in MNAN mutagenicity. The test MAbs also inhibited the microsome-catalyzed demethylation and depentylation of MNAN by up to 83%, confirming previous results. Four comparisons between individual mutagenic and metabolic results supported the view that depentylation of MNAN was more critical for its mutagenicity than was demethylation, e.g., with 3-methylcholanthrene- and Aroclor-induced microsomes, MAb 1-7-1 to CYP 1A1/1A2 inhibited mutagenesis and depentylation, but did not affect demethylation.
在未诱导和诱导大鼠的肝微粒体存在的情况下,检测了致癌物甲基正戊基亚硝胺(MNAN)对鼠伤寒沙门氏菌TA 1535的致突变性。突变数量的顺序为:苯巴比妥和多氯联苯诱导的微粒体>3-甲基胆蒽和异烟肼诱导的微粒体>未诱导的微粒体。MNAN代谢物4-羟基-MNAN无致突变性。使用每种类型的诱导肝微粒体,我们检测了四种抑制细胞色素P450的单克隆抗体(MAb)对MNAN致突变性的影响。这些单克隆抗体在七种单克隆抗体-微粒体组合中可将MNAN致突变性抑制高达49%。综合来看,这些结果表明,在苯巴比妥诱导的微粒体中,CYP(P450)2B1/2B2导致了MNAN致突变性的一半,CYP 2C11导致了四分之一;在3-甲基胆蒽诱导的微粒体中,CYP 1A1/1A2约占致突变性的40%;在多氯联苯诱导的微粒体中,CYP 2B1/2B2占一半,CYP 1A1/1A2和2C11占较小比例的致突变性;在异烟肼诱导的微粒体中,CYP 1A1/1A2约占致突变性的30%。在异烟肼诱导的微粒体中,针对CYP 2B1/2B1的单克隆抗体2-66-3意外地使MNAN致突变性增加了219%,单克隆抗体1-68-11使MNAN致突变性适度增加。测试的单克隆抗体还可将微粒体催化的MNAN去甲基化和去戊基化抑制高达83%,证实了先前的结果。个体致突变性和代谢结果之间的四项比较支持了这样一种观点,即MNAN的去戊基化对其致突变性比去甲基化更为关键,例如,在3-甲基胆蒽和多氯联苯诱导的微粒体中,针对CYP 1A1/1A2的单克隆抗体1-7-1抑制了诱变和去戊基化,但不影响去甲基化。